Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

被引：28

作者：

Kanesvaran, R. ^{[1
,2
]}

Castro, E. ^{[3
]}

Wong, A. ^{[4
]}

Fizazi, K. ^{[5
]}

Chua, M. L. K. ^{[2
,6
,7
]}

Zhu, Y. ^{[8
]}

Malhotra, H. ^{[9
]}

Miura, Y. ^{[10
]}

Lee, J. L. ^{[11
]}

Chong, F. L. T. ^{[12
]}

Pu, Y-S ^{[13
]}

Yen, C-C ^{[14
,15
,16
]}

Saad, M. ^{[17
]}

Lee, H. J. ^{[18
]}

Kitamura, H. ^{[19
]}

Prabhash, K. ^{[20
]}

Zou, Q. ^{[21
]}

Curigliano, G. ^{[22
,23
]}

Poon, E. ^{[1
]}

Choo, S. P. ^{[1
,24
]}

Peters, S. ^{[25
]}

Lim, E. ^{[1
]}

Yoshino, T. ^{[26
]}

Pentheroudakis, G. ^{[27
]}

机构：

[1] Natl Canc Ctr Singapore, Div Med Oncol, 11 Hosp Crescent, Singapore 169610, Singapore

[2] Duke NUS Med Sch, Oncol Acad Programme, Singapore, Singapore

[3] Virgen de la Victoria Univ Hosp, Inst Biomed Res Malaga, Dept Med Oncol, Malaga, Spain

[4] Natl Univ Canc Inst, Div Med Oncol, Singapore, Singapore

[5] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[6] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore

[7] Natl Canc Ctr Singapore, Div Med Sci, Singapore, Singapore

[8] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China

[9] Mahatma Gandhi Univ Med Sci & Technol, Mahatma Gandhi Med Coll Hosp, Sri Ram Canc Ctr, Dept Med Oncol, Jaipur, Rajasthan, India

[10] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

[11] Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea

[12] Sabah Women & Childrens Hosp, Dept Radiotherapy & Oncol, Kota Kinabalu, Sabah, Malaysia

[13] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan

[14] Taipei Vet Gen Hosp, Dept Med Res, Div Clin Res, Taipei, Taiwan

[15] Taipei Vet Gen Hosp, Ctr Immunooncol, Dept Oncol, Div Med Oncol, Taipei, Taiwan

[16] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan

[17] Univ Malaya, Med Ctr, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia

[18] Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Med Oncol, Coll Med, Daejeon, South Korea

[19] Univ Toyama, Fac Med, Dept Urol, Toyama, Japan

[20] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India

[21] Nanjing Med Univ, Affiliated Canc Hosp, Dept Urol, Nanjing, Peoples R China

[22] European Inst Oncol, IRCCS, Milan, Italy

[23] Univ Milan, Milan, Italy

[24] Curie Oncol, Med Oncol, Singapore, Singapore

[25] Lausanne Univ Hosp CHUV, Oncol Dept, Lausanne, Switzerland

[26] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[27] ESMO, Lugano, Switzerland

来源：

ESMO OPEN | 2022年 / 7卷 / 04期

关键词：

ESMO; guidelines; Pan-Asian; prostate cancer; treatment; ANDROGEN-DEPRIVATION THERAPY; ACETATE PLUS PREDNISONE; RADICAL PROSTATECTOMY; ABIRATERONE ACETATE; INCREASED SURVIVAL; RADIATION-THERAPY; DOUBLE-BLIND; OPEN-LABEL; RADIOTHERAPY; ANTIGEN;

D O I：

10.1016/j.esmoop.2022.100518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.

引用

页数：18

共 139 条

[1] Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial [J].

Ahlgren, Goran M. ;

Flodgren, Per ;

Tammela, Teuvo L. J. ;

Kellokumpu-Lehtinen, Pirkko ;

Borre, Michael ;

Angelsen, Anders ;

Iversen, Jon Reidar ;

Sverrisdottir, Asgerdur ;

Jonsson, Eirikur ;

Sengelov, Lisa .

EUROPEAN UROLOGY, 2018, 73 (06) :870-876

[2] Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study [J].

Ahmed, Hashim U. ;

Bosaily, Ahmed El-Shater ;

Brown, Louise C. ;

Gabe, Rhian ;

Kaplan, Richard ;

Parmar, Mahesh K. ;

Collaco-Moraes, Yolanda ;

Ward, Katie ;

Hindley, Richard G. ;

Freeman, Alex ;

Kirkham, Alex P. ;

Oldroyd, Robert ;

Parker, Chris ;

Emberton, Mark .

LANCET, 2017, 389 (10071) :815-822

[3] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J].

Amin, Mahul B. ;

Greene, Frederick L. ;

Edge, Stephen B. ;

Compton, Carolyn C. ;

Gershenwald, Jeffrey E. ;

Brookland, Robert K. ;

Meyer, Laura ;

Gress, Donna M. ;

Byrd, David R. ;

Winchester, David P. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) :93-99

[4] A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts [J].

Ankerst, Donna P. ;

Straubinger, Johanna ;

Selig, Katharina ;

Guerrios, Lourdes ;

De Hoedt, Amanda ;

Hernandez, Javier ;

Liss, Michael A. ;

Leach, Robin J. ;

Freedland, Stephen J. ;

Kattan, Michael W. ;

Nam, Robert ;

Haese, Alexander ;

Montorsi, Francesco ;

Boorjian, Stephen A. ;

Cooperberg, Matthew R. ;

Poyet, Cedric ;

Vertosick, Emily ;

Vickers, Andrew J. .

EUROPEAN UROLOGY, 2018, 74 (02) :197-203

[5]

[Anonymous], 2015, J CLIN ONCOL

[6]

[Anonymous], 2018, EMA restricts use of prostate cancer medicine Xofigo

[7]

[Anonymous], 2022, RISK STRATIFICATION

[8]

[Anonymous], 2018, ANN ONCOL

[9] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].

Antonarakis, Emmanuel S. ;

Piulats, Josep M. ;

Gross-Goupil, Marine ;

Goh, Jeffrey ;

Ojamaa, Kristiina ;

Hoimes, Christopher J. ;

Vaishampayan, Ulka ;

Berger, Ranaan ;

Sezer, Ahmet ;

Alanko, Tuomo ;

de Wit, Ronald ;

Li, Chunde ;

Omlin, Aurelius ;

Procopio, Giuseppe ;

Fukasawa, Satoshi ;

Tabata, Ken-ichi ;

Park, Se Hoon ;

Feyerabend, Susan ;

Drake, Charles G. ;

Wu, Haiyan ;

Qiu, Ping ;

Kim, Jeri ;

Poehlein, Christian ;

de Bono, Johann Sebastian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[10] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].

Armstrong, Andrew J. ;

Szmulewitz, Russell Z. ;

Petrylak, Daniel P. ;

Holzbeierlein, Jeffrey ;

Villers, Arnauld ;

Azad, Arun ;

Alcaraz, Antonio ;

Alekseev, Boris ;

Iguchi, Taro ;

Shore, Neal D. ;

Rosbrook, Brad ;

Sugg, Jennifer ;

Baron, Benoit ;

Chen, Lucy ;

Stenzl, Arnulf .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+

← 1 2 3 4 5 6 7 8 9 10 →